Loughborough University
Browse

Cannabidiol oil ingested as sublingual drops or within gelatin capsules shows similar pharmacokinetic profiles in healthy males

Download (378.65 kB)
journal contribution
posted on 2025-04-02, 11:07 authored by Drusus Johnson, Mark Funnell, Liam HeaneyLiam Heaney, Tom CableTom Cable, Patrick WheelerPatrick Wheeler, Stephen BaileyStephen Bailey, Tom CliffordTom Clifford, Lewis JamesLewis James

Introduction: Cannabidiol (CBD) is a nonintoxicating phytocannabinoid used in clinical treatments and sold widely in consumer products. CBD products may be designed for sublingual or oral delivery, but it is unclear whether either is advantageous for CBD absorption. This study compared CBD pharmacokinetics after providing CBD oil as sublingual drops and within orally ingested gelatin capsules, at a dose relevant to consumer products.

Materials and Methods: Eight males completed three conditions in a participant-blinded, randomized crossover design. Participants received the following combinations of placebo and CBD-containing (69 mg/mL) hemp oil in capsules and as sublingual drops: placebo capsules/placebo drops (Placebo), CBD capsules/placebo drops (CBD-Caps), and placebo capsules/CBD drops (CBD-Drops). Blood samples, blood pressure, and subjective scales were obtained/completed hourly for 6 h and at 24 h.

Discussion: Plasma CBD concentrations were not different between CBD-Caps and CBD-Drops (interaction effect p=0.76). Peak CBD concentration (28.0±15.6 vs. 24.0±22.2 ng/mL), time of peak CBD concentration (4±1 vs. 4±2 h), and area under the concentration curve (45.3±20.3 vs. 41.8±23.3 ng/mL·6 h) were not different between conditions (p≥0.25). Cardiometabolic outcomes (plasma glucose/triacylglycerol, heart rate, blood pressure), liver function (plasma alanine aminotransferase/aspartate aminotransferase), kidney function (plasma creatinine), and subjective feelings/symptoms were not different between conditions (p≥0.07).

Conclusions: Plasma CBD profiles were comparable between CBD-Caps and CBD-Drops, suggesting that there were not meaningful differences in routes of CBD absorption between conditions. This implies that CBD oil delivered sublingually is swallowed before oral mucosal CBD absorption occurs, which may have implications for research design, CBD product design, and consumer product choice.

Funding

Bridge Farm Nurseries ltd., Spalding, UK

History

School

  • Sport, Exercise and Health Sciences

Published in

Cannabis and Cannabinoid Research

Volume

9

Issue

5

Pages

e1423 - e1432

Publisher

Mary Ann Liebert Inc

Version

  • AM (Accepted Manuscript)

Rights holder

© Mary Ann Liebert, Inc.

Publisher statement

This is the accepted version of the following article which has now been formally published in final form at Cannabis and Cannabinoid Research at https://doi.org/10.1089/can.2023.0117. This original submission version of the article may be used for non-commercial purposes in accordance with the Mary Ann Liebert, Inc., publishers’ self-archiving terms and conditions.

Publication date

2023-09-22

Copyright date

2023

ISSN

2578-5125

eISSN

2378-8763

Language

  • en

Depositor

Dr Lewis James. Deposit date: 18 March 2025

Usage metrics

    Loughborough Publications

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC